



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Pollak *et al.*

FILED: December 18, 2001

SERIAL NO.: 10/025,350

FOR: Circulating Insulin-Like Growth Factor-I
and Prostate Cancer Risk

§
§
§
§
§
§
§

ART UNIT:

1642

EXAMINER:

Holleran, Anne L.

DOCKET:

28758.57

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RESPONSE UNDER 37 CFR 1.111

Dear Sir:

In response to the Office Action mailed December 7, 2005 please consider the following remarks. Reconsideration of the pending claims is respectfully requested.

REMARKS

Status of the Claims

Claims 21-27 are pending. Claims 21-27 are rejected.

The 35 U.S.C. §112, first paragraph rejections

Claims 21-27 are rejected under 35 U.S.C. §112, first paragraph, because the specification, while being enabling for methods of predicting a doubling of risk for